BioLight Life Sciences

BioLight Life Sciences Investments Ltd., founded in 2005 and based in Tel Aviv, Israel, focuses on investing in and commercializing biomedical innovations categorized into specific medical clusters. Currently, the company manages two main clusters: ophthalmology and cancer diagnostics. In ophthalmology, BioLight fully owns XLVision Sciences, which offers innovative technologies such as IOPtimate™, a noninvasive surgical treatment for glaucoma, TeaRx, a diagnostic test for dry-eye syndrome, and Eye-D™, a controlled release drug-delivery implant platform. In the cancer diagnostics sector, BioLight holds a controlling stake in Micromedic, which provides diagnostic tests for various cancers, including colorectal, cervical, breast, bladder, and lung cancers. The firm aims to support seed-stage to later-stage companies within the advanced medical devices, medication, diagnostics, and digital healthcare markets.